Vertex Pharmaceuticals Inc. closed 13.15% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach ...

Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at any time, the Boston-based ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceuticals has ...

Continue » This stock is Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that's delivered a long track record of growth and profitability thanks to its leadership in the cystic fibrosis (CF ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $114.31 billion, has established itself as a dominant force in the treatment ...

I am privileged to be joined today by Vertex's CEO, Reshma Kewalramani ... But I've been -- I've visited our office and I visited the sites that are qualified and are part of our ATC network.

In addition to Bernstein, Vertex Pharmaceuticals also received a Hold from Erste Group’s Hans Engel in a report issued on May 23. However, on May 21, Bank of America Securities maintained a Buy ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and ...